Single-Arm Clinical Study of EZH2i in Combination With Glofitamab + GemOx in Patients With Relapsed/ Refractory DLBCL

NCT07643805 | Not Yet Recruiting Phase 1

• 1 other identifier: MA-DLBCL-II-005
• Study Type: interventional
• Target: 46
• Locations: 1 country
• Sites: 1

Brief Summary

Single-Arm Clinical Study of Zeprumetostat in Combination with Glofitamab + GemOx in Patients with Relapsed/ Refractory DLBCL

Conditions

DLBCL

Outcome Measures

Primary Outcomes (1)

• Complete response rate, CRR

  From first dose to end of treatment (assessed up to 12 months)

Study Arms (1)

EZH2i+Glofit-GemOx

EXPERIMENTAL

Drug: EZH2i+GLofit-GemOx

Interventions

EZH2i+GLofit-GemOx DRUG

EZH2i+GLofit-GemOx

EZH2i+Glofit-GemOx

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age ≥ 18 years, male or female;
• Histologically confirmed diffuse large B-cell lymphoma (DLBCL);
• Relapsed/refractory (R/R) disease；
• At least one prior line of therapy containing rituximab;
• Subjects must have at least one measurable lesion;
• ECOG PS 0-2;
• Life expectancy ≥ 3 months;
• Adequate organ and bone marrow function, without severe hematopoietic abnormalities or cardiac, pulmonary, hepatic, renal, thyroid dysfunction, or immunodeficiencies;
• Female subjects of childbearing potential (WOCBP) must have a negative serum pregnancy test within 7 days prior to the first dose of study drug; WOCBP subjects and male subjects with WOCBP partners must agree to practice effective contraceptive measures from the time of signing the informed consent form (ICF) until 6 months after the last dose of study drug;
• Signed informed consent form (ICF), voluntarily agreeing to participate in this study.

You may not qualify if:

• Patient is a candidate for hematopoietic stem cell transplantation.
• Prior allogeneic hematopoietic stem cell transplantation.
• Primary or secondary central nervous system (CNS) lymphoma or history of CNS lymphoma.
• History of severe hypersensitivity or anaphylactic reaction to humanized or murine monoclonal antibodies.
• Prior treatment with an EZH2 inhibitor, and/or an anti-CD20 and CD3 bispecific antibody, and/or GemOx (gemcitabine and oxaliplatin).
• History of other malignancies within the past 2 years requiring systemic therapy.
• Receipt of systemic anti-neoplastic therapy, including chemotherapy, immunotherapy, biologic therapy, etc., within 14 days prior to the start of study treatment.
• Major surgery (excluding diagnostic procedures) within 28 days prior to the start of study treatment.
• Presence of any active, known, or suspected autoimmune disease. (Subjects who are in a stable condition and do not require systemic immunosuppressive therapy are permitted to enroll.)
• Use of immunosuppressive agents, including systemic corticosteroids, within 14 days prior to study drug administration (use of ≤10 mg/day prednisone or equivalent is permitted).
• Any active infection requiring systemic anti-infective therapy within 14 days prior to the start of study treatment.
• Presence of any uncontrolled comorbid conditions that may affect compliance with the study protocol, including major cardiovascular disease, bleeding disorders, etc.
• Active hepatitis B virus (HBV) infection (HBV DNA positive) or hepatitis C virus (HCV) infection.
• Known history of human immunodeficiency virus (HIV) positivity.
• Inability to swallow oral medication, or any other factor affecting oral drug administration and absorption.

Sponsors & Collaborators

• The First Affiliated Hospital with Nanjing Medical University: lead

Study Sites (1)

The First Affiliated Hospital with Nanjing Medical University

Nanjing, Jiangsu, 210029, China

Location

Central Study Contacts

Lei Fan

CONTACT

13813976136; fanlei3014@126.com

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Director of lymphoma center

Study Record Dates

• First Submitted: June 4, 2026
• First Posted: June 12, 2026
• Study Start: June 1, 2026
• Primary Completion (Estimated): January 30, 2028
• Study Completion (Estimated): September 30, 2030
• Last Updated: June 12, 2026

Record last verified: 2026-06

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)